VTYX · Insider Trading
Ventyx Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by VTYX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Allison Hulme | Director | D | −129,364 deriv. | — |
| 2026-03-04 | Roy Gonzales | Senior VP, Finance | D | −5,313 | — |
| 2026-03-04 | Onaiza Cadoret-Manier | Director | D | −129,364 deriv. | — |
| 2026-03-04 | John Nuss | CHIEF SCIENTIFIC OFFICER | D | −489,481 | — |
| 2026-03-04 | William Richard White | Director | D | −249,882 deriv. | — |
| 2026-03-04 | Matthew Richard Moore | Chief Operating Officer | D | −465,000 deriv. | — |
| 2026-03-04 | Somu Subramaniam | Director | D | −3,337,495 | — |
| 2026-03-04 | Raju Mohan | CEO AND PRESIDENT | D | −2,372,863 | — |
| 2026-03-04 | Mark S Forman | Chief Medical Officer | D | −6,000 | — |
| 2026-03-04 | Sheila Gujrathi | Director | D | −130,000 | — |
| 2026-03-03 | Somu Subramaniam | Director | J | −694,718 | — |
| 2025-12-19 | John Nuss | CHIEF SCIENTIFIC OFFICER | MIXED | +22,255 | −$97.84K |
| 2025-12-19 | Raju Mohan | CEO AND PRESIDENT | MIXED | +69,323 | −$365.46K |
| 2025-11-19 | Roy Gonzales | Senior VP, Finance | A | +1,767 | +$1.82K |
| 2025-11-19 | Mark S Forman | Chief Medical Officer | A | +3,000 | +$3.09K |
| 2025-06-06 | William Richard White | Director | A | +40,000 deriv. | — |
| 2025-06-06 | Sheila Gujrathi | Director | A | +40,000 deriv. | — |
| 2025-06-06 | Onaiza Cadoret-Manier | Director | A | +40,000 deriv. | — |
| 2025-06-06 | Allison Hulme | Director | A | +40,000 deriv. | — |
| 2025-06-06 | Somu Subramaniam | Director | A | +40,000 deriv. | — |
| 2025-05-16 | Roy Gonzales | Senior VP, Finance | A | +1,750 | +$1.80K |
| 2025-05-16 | Mark S Forman | Chief Medical Officer | A | +3,000 | +$3.09K |
| 2025-04-03 | John Nuss | CHIEF SCIENTIFIC OFFICER | Sell | −1,887 | −$2.02K |
| 2025-04-01 | Raju Mohan | CEO AND PRESIDENT | M | +11,844 | — |
| 2025-04-01 | John Nuss | CHIEF SCIENTIFIC OFFICER | M | +4,531 | — |
| 2025-04-01 | Somu Subramaniam | Director | J | −1,335,450 | — |
| 2025-03-12 | Somu Subramaniam | Director | J | −1,735,306 | — |
| 2025-01-03 | Matthew Richard Moore | Chief Operating Officer | A | +145,000 deriv. | — |
| 2025-01-03 | John Nuss | CHIEF SCIENTIFIC OFFICER | A | +415,104 deriv. | — |
| 2025-01-03 | Mark S Forman | Chief Medical Officer | A | +85,000 deriv. | — |
| 2025-01-03 | Roy Gonzales | Senior VP, Finance | A | +126,700 deriv. | — |
| 2025-01-03 | Raju Mohan | CEO AND PRESIDENT | A | +700,000 deriv. | — |
| 2024-12-30 | John Nuss | CHIEF SCIENTIFIC OFFICER | Sell | −21,119 | −$49.84K |
| 2024-12-26 | Sheila Gujrathi | Director | Buy | +130,000 | +$300.57K |
| 2024-12-19 | John Nuss | CHIEF SCIENTIFIC OFFICER | MIXED | +21,769 | −$29.68K |
| 2024-12-19 | Raju Mohan | CEO AND PRESIDENT | M | +116,668 | — |
| 2024-12-11 | John Nuss | CHIEF SCIENTIFIC OFFICER | M | +198,934 | +$39.79K |
| 2024-11-25 | Raju Mohan | CEO AND PRESIDENT | Buy | +500,000 | +$959.89K |
| 2024-08-13 | Mark S Forman | Chief Medical Officer | A | +350,000 deriv. | — |
| 2024-06-26 | Somu Subramaniam | Director | J | −641,327 | — |
| 2024-06-26 | NSV Partners III GP LLC | 10%+ Owner | J | −1,282,654 | — |
| 2024-06-11 | Raju Mohan | CEO AND PRESIDENT | M | +96,778 | +$19.36K |
| 2024-06-07 | Onaiza Cadoret-Manier | Director | A | +33,000 deriv. | — |
| 2024-06-07 | Sheila Gujrathi | Director | A | +33,000 deriv. | — |
| 2024-06-07 | William Richard White | Director | A | +33,000 deriv. | — |
| 2024-06-07 | Allison Hulme | Director | A | +33,000 deriv. | — |
| 2024-06-07 | Somu Subramaniam | Director | A | +33,000 deriv. | — |
| 2024-05-17 | Matthew Richard Moore | Chief Operating Officer | A | +320,000 deriv. | — |
| 2024-04-16 | NSV Partners III GP LLC | 10%+ Owner | J | −1,390,678 | — |
| 2024-04-16 | Somu Subramaniam | Director | J | −695,339 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William Richard White | Director | 7,027 | $98.31K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VTYX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.